miRNA panel from HER2+ and CD24+ plasma extracellular vesicle subpopulations as biomarkers of early-stage breast cancer
Background Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Ther...
Saved in:
| Published in | Breast cancer research : BCR Vol. 27; no. 1; pp. 90 - 14 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
22.05.2025
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1465-542X 1465-5411 1465-542X |
| DOI | 10.1186/s13058-025-02029-2 |
Cover
| Abstract | Background
Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Therefore, there is a need for noninvasive, blood-based diagnostics that can accurately assess risk of malignancy for women with indeterminate lesions identified by mammography, such as BI-RADS category 4 breast lesions. The aim of this study is to identify biomarkers from multiplexed extracellular vesicle liquid biopsy that can accurately classify mammographically detected BI-RADS 4 lesions.
Methods
We analyzed plasma from 113 prospectively enrolled subjects with BI-RADS 4 breast lesions, including 86 women with benign lesions and 27 women with malignant lesions (including 12 with stage I invasive carcinoma and 14 with ductal carcinoma
in situ
). None of the invasive carcinomas were metastatic. From each plasma sample, we used track etched magnetic nanopore technology to separately isolate HER2 and CD24 expressing extracellular vesicles (EVs) and measured their miRNA cargo using next-generation sequencing. We evaluated the performance of EV-miRNA biomarkers for classifying malignancy and applied LASSO classification to identify a panel of four complementary EV miRNA biomarkers that we validated by qPCR.
Results
We identified 19 differentially enriched miRNA from HER2+ EVs and 11 differentially enriched miRNA from CD24+ EVs of women with malignant lesions compared to benign lesions. We observed individual miRNA with an AUC of up to 0.87 for miR-340-5p from HER2+ EVs and 0.75 for miR-223-3p from CD24+ EVs. LASSO classification selected a panel of four complementary EV miRNA for classifying breast cancer: miR-340-5p (HER2+ EVs), miR-598-3p (CD24+), miR-15b-5p (HER2+), and miR-126-3p (CD24+).
Conclusions
HER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions. |
|---|---|
| AbstractList | BackgroundMammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Therefore, there is a need for noninvasive, blood-based diagnostics that can accurately assess risk of malignancy for women with indeterminate lesions identified by mammography, such as BI-RADS category 4 breast lesions. The aim of this study is to identify biomarkers from multiplexed extracellular vesicle liquid biopsy that can accurately classify mammographically detected BI-RADS 4 lesions.MethodsWe analyzed plasma from 113 prospectively enrolled subjects with BI-RADS 4 breast lesions, including 86 women with benign lesions and 27 women with malignant lesions (including 12 with stage I invasive carcinoma and 14 with ductal carcinoma in situ). None of the invasive carcinomas were metastatic. From each plasma sample, we used track etched magnetic nanopore technology to separately isolate HER2 and CD24 expressing extracellular vesicles (EVs) and measured their miRNA cargo using next-generation sequencing. We evaluated the performance of EV-miRNA biomarkers for classifying malignancy and applied LASSO classification to identify a panel of four complementary EV miRNA biomarkers that we validated by qPCR.ResultsWe identified 19 differentially enriched miRNA from HER2+ EVs and 11 differentially enriched miRNA from CD24+ EVs of women with malignant lesions compared to benign lesions. We observed individual miRNA with an AUC of up to 0.87 for miR-340-5p from HER2+ EVs and 0.75 for miR-223-3p from CD24+ EVs. LASSO classification selected a panel of four complementary EV miRNA for classifying breast cancer: miR-340-5p (HER2+ EVs), miR-598-3p (CD24+), miR-15b-5p (HER2+), and miR-126-3p (CD24+).ConclusionsHER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions. Background Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Therefore, there is a need for noninvasive, blood-based diagnostics that can accurately assess risk of malignancy for women with indeterminate lesions identified by mammography, such as BI-RADS category 4 breast lesions. The aim of this study is to identify biomarkers from multiplexed extracellular vesicle liquid biopsy that can accurately classify mammographically detected BI-RADS 4 lesions. Methods We analyzed plasma from 113 prospectively enrolled subjects with BI-RADS 4 breast lesions, including 86 women with benign lesions and 27 women with malignant lesions (including 12 with stage I invasive carcinoma and 14 with ductal carcinoma in situ). None of the invasive carcinomas were metastatic. From each plasma sample, we used track etched magnetic nanopore technology to separately isolate HER2 and CD24 expressing extracellular vesicles (EVs) and measured their miRNA cargo using next-generation sequencing. We evaluated the performance of EV-miRNA biomarkers for classifying malignancy and applied LASSO classification to identify a panel of four complementary EV miRNA biomarkers that we validated by qPCR. Results We identified 19 differentially enriched miRNA from HER2+ EVs and 11 differentially enriched miRNA from CD24+ EVs of women with malignant lesions compared to benign lesions. We observed individual miRNA with an AUC of up to 0.87 for miR-340-5p from HER2+ EVs and 0.75 for miR-223-3p from CD24+ EVs. LASSO classification selected a panel of four complementary EV miRNA for classifying breast cancer: miR-340-5p (HER2+ EVs), miR-598-3p (CD24+), miR-15b-5p (HER2+), and miR-126-3p (CD24+). Conclusions HER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions. Keywords: Early detection biomarkers, BI-RADS 4 breast lesions, Extracellular vesicles, Liquid biopsy, MiRNA sequencing Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Therefore, there is a need for noninvasive, blood-based diagnostics that can accurately assess risk of malignancy for women with indeterminate lesions identified by mammography, such as BI-RADS category 4 breast lesions. The aim of this study is to identify biomarkers from multiplexed extracellular vesicle liquid biopsy that can accurately classify mammographically detected BI-RADS 4 lesions.BACKGROUNDMammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Therefore, there is a need for noninvasive, blood-based diagnostics that can accurately assess risk of malignancy for women with indeterminate lesions identified by mammography, such as BI-RADS category 4 breast lesions. The aim of this study is to identify biomarkers from multiplexed extracellular vesicle liquid biopsy that can accurately classify mammographically detected BI-RADS 4 lesions.We analyzed plasma from 113 prospectively enrolled subjects with BI-RADS 4 breast lesions, including 86 women with benign lesions and 27 women with malignant lesions (including 12 with stage I invasive carcinoma and 14 with ductal carcinoma in situ). None of the invasive carcinomas were metastatic. From each plasma sample, we used track etched magnetic nanopore technology to separately isolate HER2 and CD24 expressing extracellular vesicles (EVs) and measured their miRNA cargo using next-generation sequencing. We evaluated the performance of EV-miRNA biomarkers for classifying malignancy and applied LASSO classification to identify a panel of four complementary EV miRNA biomarkers that we validated by qPCR.METHODSWe analyzed plasma from 113 prospectively enrolled subjects with BI-RADS 4 breast lesions, including 86 women with benign lesions and 27 women with malignant lesions (including 12 with stage I invasive carcinoma and 14 with ductal carcinoma in situ). None of the invasive carcinomas were metastatic. From each plasma sample, we used track etched magnetic nanopore technology to separately isolate HER2 and CD24 expressing extracellular vesicles (EVs) and measured their miRNA cargo using next-generation sequencing. We evaluated the performance of EV-miRNA biomarkers for classifying malignancy and applied LASSO classification to identify a panel of four complementary EV miRNA biomarkers that we validated by qPCR.We identified 19 differentially enriched miRNA from HER2+ EVs and 11 differentially enriched miRNA from CD24+ EVs of women with malignant lesions compared to benign lesions. We observed individual miRNA with an AUC of up to 0.87 for miR-340-5p from HER2+ EVs and 0.75 for miR-223-3p from CD24+ EVs. LASSO classification selected a panel of four complementary EV miRNA for classifying breast cancer: miR-340-5p (HER2+ EVs), miR-598-3p (CD24+), miR-15b-5p (HER2+), and miR-126-3p (CD24+).RESULTSWe identified 19 differentially enriched miRNA from HER2+ EVs and 11 differentially enriched miRNA from CD24+ EVs of women with malignant lesions compared to benign lesions. We observed individual miRNA with an AUC of up to 0.87 for miR-340-5p from HER2+ EVs and 0.75 for miR-223-3p from CD24+ EVs. LASSO classification selected a panel of four complementary EV miRNA for classifying breast cancer: miR-340-5p (HER2+ EVs), miR-598-3p (CD24+), miR-15b-5p (HER2+), and miR-126-3p (CD24+).HER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions.CONCLUSIONSHER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions. Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Therefore, there is a need for noninvasive, blood-based diagnostics that can accurately assess risk of malignancy for women with indeterminate lesions identified by mammography, such as BI-RADS category 4 breast lesions. The aim of this study is to identify biomarkers from multiplexed extracellular vesicle liquid biopsy that can accurately classify mammographically detected BI-RADS 4 lesions. We analyzed plasma from 113 prospectively enrolled subjects with BI-RADS 4 breast lesions, including 86 women with benign lesions and 27 women with malignant lesions (including 12 with stage I invasive carcinoma and 14 with ductal carcinoma in situ). None of the invasive carcinomas were metastatic. From each plasma sample, we used track etched magnetic nanopore technology to separately isolate HER2 and CD24 expressing extracellular vesicles (EVs) and measured their miRNA cargo using next-generation sequencing. We evaluated the performance of EV-miRNA biomarkers for classifying malignancy and applied LASSO classification to identify a panel of four complementary EV miRNA biomarkers that we validated by qPCR. We identified 19 differentially enriched miRNA from HER2+ EVs and 11 differentially enriched miRNA from CD24+ EVs of women with malignant lesions compared to benign lesions. We observed individual miRNA with an AUC of up to 0.87 for miR-340-5p from HER2+ EVs and 0.75 for miR-223-3p from CD24+ EVs. LASSO classification selected a panel of four complementary EV miRNA for classifying breast cancer: miR-340-5p (HER2+ EVs), miR-598-3p (CD24+), miR-15b-5p (HER2+), and miR-126-3p (CD24+). HER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions. Background Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Therefore, there is a need for noninvasive, blood-based diagnostics that can accurately assess risk of malignancy for women with indeterminate lesions identified by mammography, such as BI-RADS category 4 breast lesions. The aim of this study is to identify biomarkers from multiplexed extracellular vesicle liquid biopsy that can accurately classify mammographically detected BI-RADS 4 lesions. Methods We analyzed plasma from 113 prospectively enrolled subjects with BI-RADS 4 breast lesions, including 86 women with benign lesions and 27 women with malignant lesions (including 12 with stage I invasive carcinoma and 14 with ductal carcinoma in situ ). None of the invasive carcinomas were metastatic. From each plasma sample, we used track etched magnetic nanopore technology to separately isolate HER2 and CD24 expressing extracellular vesicles (EVs) and measured their miRNA cargo using next-generation sequencing. We evaluated the performance of EV-miRNA biomarkers for classifying malignancy and applied LASSO classification to identify a panel of four complementary EV miRNA biomarkers that we validated by qPCR. Results We identified 19 differentially enriched miRNA from HER2+ EVs and 11 differentially enriched miRNA from CD24+ EVs of women with malignant lesions compared to benign lesions. We observed individual miRNA with an AUC of up to 0.87 for miR-340-5p from HER2+ EVs and 0.75 for miR-223-3p from CD24+ EVs. LASSO classification selected a panel of four complementary EV miRNA for classifying breast cancer: miR-340-5p (HER2+ EVs), miR-598-3p (CD24+), miR-15b-5p (HER2+), and miR-126-3p (CD24+). Conclusions HER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions. Abstract Background Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Therefore, there is a need for noninvasive, blood-based diagnostics that can accurately assess risk of malignancy for women with indeterminate lesions identified by mammography, such as BI-RADS category 4 breast lesions. The aim of this study is to identify biomarkers from multiplexed extracellular vesicle liquid biopsy that can accurately classify mammographically detected BI-RADS 4 lesions. Methods We analyzed plasma from 113 prospectively enrolled subjects with BI-RADS 4 breast lesions, including 86 women with benign lesions and 27 women with malignant lesions (including 12 with stage I invasive carcinoma and 14 with ductal carcinoma in situ). None of the invasive carcinomas were metastatic. From each plasma sample, we used track etched magnetic nanopore technology to separately isolate HER2 and CD24 expressing extracellular vesicles (EVs) and measured their miRNA cargo using next-generation sequencing. We evaluated the performance of EV-miRNA biomarkers for classifying malignancy and applied LASSO classification to identify a panel of four complementary EV miRNA biomarkers that we validated by qPCR. Results We identified 19 differentially enriched miRNA from HER2+ EVs and 11 differentially enriched miRNA from CD24+ EVs of women with malignant lesions compared to benign lesions. We observed individual miRNA with an AUC of up to 0.87 for miR-340-5p from HER2+ EVs and 0.75 for miR-223-3p from CD24+ EVs. LASSO classification selected a panel of four complementary EV miRNA for classifying breast cancer: miR-340-5p (HER2+ EVs), miR-598-3p (CD24+), miR-15b-5p (HER2+), and miR-126-3p (CD24+). Conclusions HER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions. Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Therefore, there is a need for noninvasive, blood-based diagnostics that can accurately assess risk of malignancy for women with indeterminate lesions identified by mammography, such as BI-RADS category 4 breast lesions. The aim of this study is to identify biomarkers from multiplexed extracellular vesicle liquid biopsy that can accurately classify mammographically detected BI-RADS 4 lesions. We analyzed plasma from 113 prospectively enrolled subjects with BI-RADS 4 breast lesions, including 86 women with benign lesions and 27 women with malignant lesions (including 12 with stage I invasive carcinoma and 14 with ductal carcinoma in situ). None of the invasive carcinomas were metastatic. From each plasma sample, we used track etched magnetic nanopore technology to separately isolate HER2 and CD24 expressing extracellular vesicles (EVs) and measured their miRNA cargo using next-generation sequencing. We evaluated the performance of EV-miRNA biomarkers for classifying malignancy and applied LASSO classification to identify a panel of four complementary EV miRNA biomarkers that we validated by qPCR. We identified 19 differentially enriched miRNA from HER2+ EVs and 11 differentially enriched miRNA from CD24+ EVs of women with malignant lesions compared to benign lesions. We observed individual miRNA with an AUC of up to 0.87 for miR-340-5p from HER2+ EVs and 0.75 for miR-223-3p from CD24+ EVs. LASSO classification selected a panel of four complementary EV miRNA for classifying breast cancer: miR-340-5p (HER2+ EVs), miR-598-3p (CD24+), miR-15b-5p (HER2+), and miR-126-3p (CD24+). HER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions. |
| ArticleNumber | 90 |
| Audience | Academic |
| Author | Shen, Hanfei Yin, Melinda Conant, Emily F. Spychalski, Griffin B. Weinstein, Susan P. Yee, Stephanie Feldman, Michael D. Nayak, Anupma French, Kate Tien, Kyle Ghali, Miriyam Carpenter, Erica L. Yang, Stephanie J. Rosario, Jean Lin, Andrew A. Issadore, David |
| Author_xml | – sequence: 1 givenname: Griffin B. surname: Spychalski fullname: Spychalski, Griffin B. organization: Perelman School of Medicine, University of Pennsylvania, Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania – sequence: 2 givenname: Andrew A. surname: Lin fullname: Lin, Andrew A. organization: Perelman School of Medicine, University of Pennsylvania, Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania – sequence: 3 givenname: Stephanie J. surname: Yang fullname: Yang, Stephanie J. organization: Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania – sequence: 4 givenname: Hanfei surname: Shen fullname: Shen, Hanfei organization: Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania – sequence: 5 givenname: Jean surname: Rosario fullname: Rosario, Jean organization: Department of Biology, School of Arts and Sciences, University of Pennsylvania – sequence: 6 givenname: Kyle surname: Tien fullname: Tien, Kyle organization: Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania – sequence: 7 givenname: Kate surname: French fullname: French, Kate organization: Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania – sequence: 8 givenname: Miriyam surname: Ghali fullname: Ghali, Miriyam organization: Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania – sequence: 9 givenname: Stephanie surname: Yee fullname: Yee, Stephanie organization: Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania – sequence: 10 givenname: Melinda surname: Yin fullname: Yin, Melinda organization: Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania – sequence: 11 givenname: Michael D. surname: Feldman fullname: Feldman, Michael D. organization: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania – sequence: 12 givenname: Emily F. surname: Conant fullname: Conant, Emily F. organization: Department of Radiology, Perelman School of Medicine, University of Pennsylvania – sequence: 13 givenname: Susan P. surname: Weinstein fullname: Weinstein, Susan P. organization: Department of Radiology, Perelman School of Medicine, University of Pennsylvania – sequence: 14 givenname: Erica L. surname: Carpenter fullname: Carpenter, Erica L. organization: Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania – sequence: 15 givenname: David surname: Issadore fullname: Issadore, David organization: Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Department of Electrical and Systems Engineering, School of Engineering and Applied Science, University of Pennsylvania – sequence: 16 givenname: Anupma surname: Nayak fullname: Nayak, Anupma email: anupma.nayak@pennmedicine.upenn.edu organization: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40405296$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ku1r1TAUxotM3Iv-A36QgF-E0ZmXNkk_yeU63WAoDAW_hdMkrbm2TZe00_33prtz2xWREhpOfuchz8lzmO0NfrBZ9pLgE0IkfxsJw6XMMS3TwrTK6ZPsgBS8zMuCftt7tN_PDmPcYEyELOWzbL_ABS5pxQ-yn727_LRCIwy2Q03wPTo7vaTHCAaD1u9pcYzGDmIPyP6aAmjbdXMHAV3b6HRnUZzr0Y-pNDk_RAQR1c73EH7YEJFvkIXQ3eRxgtaiOliIE9IwaBueZ08b6KJ9cfc_yr5-OP2yPssvPn88X68ucl1yMuVMN5bShtcEOMOC88Zg0MyAYKQk2oIwlSgKyjgzBhqNCReGiZpiSYBKy46y862u8bBRY3DpcjfKg1O3BR9aBWFavChTS8qoBmKxKCQtoK7Sjhoi60prKJLWu63WONe9NdoOaSTdjujuyeC-q9ZfK0JxxYVgSeHNnULwV7ONk-pdXIaaxu_nqBjFvJKC0Cqhr_9CN34OQ5pVoggvOWMVfaBaSA7c0PjllRZRtZIFwSkAFUnUyT-o9BnbO51C1bhU32l49djpvcU_uUkA3QI6-BiDbe4RgtUSTrUNp0rhVLfhVMtl2bYpJnhobXiw9J-u35dG5Qs |
| Cites_doi | 10.1136/bmjopen-2016-012799 10.1016/j.resuscitation.2023.109937 10.1002/wnan.1835 10.1158/1078-0432.CCR-15-0654 10.1021/jacs.9b00007 10.1093/bioinformatics/btp331 10.1038/s41598-019-50084-5 10.1007/978-1-0716-3323-6_16 10.1007/s00262-023-03606-0 10.1136/jitc-2022-006013 10.1016/j.pharmthera.2021.107806 10.1186/s13058-016-0753-x 10.1038/nbt.2931 10.1093/jncics/pkz026 10.3390/cancers13051015 10.1039/D4LC00331D 10.1038/s41467-023-41132-w 10.5858/2010-0454-RAR.1 10.1002/cncr.32859 10.1002/admt.202201622 10.1002/jcp.22773 10.7717/peerj.12147 10.1158/1078-0432.CCR-19-3313 10.1111/cas.14393 10.1039/D0LC00096E 10.1186/s13058-020-01323-5 10.1093/database/bay003 10.1038/s41598-023-42726-6 10.1002/gcc.23264 10.3390/biom10010150 10.3389/fimmu.2018.00738 10.3389/fendo.2023.1202493 10.7326/0003-4819-155-8-201110180-00004 10.1016/j.clinthera.2014.05.008 10.1186/s12943-021-01330-w 10.1016/S1470-2045(14)70069-5 10.1021/acsnano.7b05503 10.1016/j.ygyno.2011.04.035 10.1186/s13059-014-0550-8 10.1155/JBB.2005.147 10.3390/jpm11080816 10.1613/jair.953 10.1002/adbi.201900307 10.1186/s12943-023-01741-x 10.1039/C7LC00955K 10.1111/jcmm.15367 10.1046/j.1365-2818.1997.1940755.x 10.1093/braincomms/fcab151 10.1186/1471-2105-12-77 10.1093/nar/gkad431 10.1038/s41596-020-00466-1 10.1021/acs.analchem.3c00624 10.1109/LSP.2014.2337313 10.3892/mmr.2019.10669 10.3322/caac.21763 10.1186/s12859-016-0994-9 10.1111/cas.15155 10.1038/s41598-023-39746-7 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13058-025-02029-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1465-542X |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_db8232ca1e074824ab9e072d18b9cca4 PMC12096773 A841046591 40405296 10_1186_s13058_025_02029_2 |
| Genre | Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: National Institute of Allergy and Infectious Diseases grantid: 5-R33-AI-147406-03 funderid: https://doi.org/10.13039/100000060 – fundername: Penn Center for Precision Medicine, University of Pennsylvania grantid: Accelerator Fund; Accelerator Fund; Accelerator Fund; Accelerator Fund; Accelerator Fund; Accelerator Fund funderid: https://doi.org/10.13039/100017830 – fundername: National Cancer Institute grantid: R33CA278551; R33CA278551 funderid: https://doi.org/10.13039/100000054 – fundername: NCI NIH HHS grantid: R33CA278551 – fundername: National Institute of Allergy and Infectious Diseases grantid: 5-R33-AI-147406-03 – fundername: Penn Center for Precision Medicine, University of Pennsylvania grantid: Accelerator Fund |
| GroupedDBID | --- 04C 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABUWG ACGFO ACGFS ACJQM ACMJI ACPRK ADBBV ADFRT ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BMSDO BPHCQ BVXVI C6C CCPQU CS3 DU5 E3Z EBD EBLON EBS EIHBH F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO ICW IHR INH INR ITC KQ8 LGEZI LOTEE NADUK NXXTH O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PUEGO RBZ ROL RPM RSV SBL SOJ TR2 U2A UKHRP WOQ AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c561t-3cfe22f6b1a630766fd0ac3da73151cea7d97442363ddafc0167d37b2081a28e3 |
| IEDL.DBID | DOA |
| ISSN | 1465-542X 1465-5411 |
| IngestDate | Wed Aug 27 01:30:20 EDT 2025 Thu Aug 21 18:30:12 EDT 2025 Fri Sep 05 16:03:46 EDT 2025 Fri Jul 18 09:41:34 EDT 2025 Tue Jun 17 21:56:12 EDT 2025 Tue May 27 03:55:21 EDT 2025 Mon May 26 01:58:02 EDT 2025 Sun Jul 06 05:04:26 EDT 2025 Sat Sep 06 07:25:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Early detection biomarkers Extracellular vesicles Liquid biopsy MiRNA sequencing BI-RADS 4 breast lesions |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c561t-3cfe22f6b1a630766fd0ac3da73151cea7d97442363ddafc0167d37b2081a28e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/db8232ca1e074824ab9e072d18b9cca4 |
| PMID | 40405296 |
| PQID | 3216563392 |
| PQPubID | 2034567 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_db8232ca1e074824ab9e072d18b9cca4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12096773 proquest_miscellaneous_3206987129 proquest_journals_3216563392 gale_infotracmisc_A841046591 gale_infotracacademiconefile_A841046591 pubmed_primary_40405296 crossref_primary_10_1186_s13058_025_02029_2 springer_journals_10_1186_s13058_025_02029_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-05-22 |
| PublicationDateYYYYMMDD | 2025-05-22 |
| PublicationDate_xml | – month: 05 year: 2025 text: 2025-05-22 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Breast cancer research : BCR |
| PublicationTitleAbbrev | Breast Cancer Res |
| PublicationTitleAlternate | Breast Cancer Res |
| PublicationYear | 2025 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | 2029_CR47 J Ko (2029_CR18) 2017; 11 2029_CR45 X Sun (2029_CR37) 2014; 21 2029_CR41 X Robin (2029_CR36) 2011; 12 V Ciravolo (2029_CR22) 2012; 227 J Ko (2029_CR58) 2020; 4 Z Yang (2029_CR19) 2020; 26 2029_CR38 G Kristiansen (2029_CR29) 2003; 9 2029_CR32 F Braet (2029_CR33) 1997; 186 2029_CR35 2029_CR8 2029_CR6 A-K Rupp (2029_CR28) 2011; 122 C Gutierrez (2029_CR27) 2011; 135 2029_CR31 2029_CR3 2029_CR1 2029_CR9 M Hu (2029_CR56) 2023; 95 SW Duffy (2029_CR2) 2020; 126 2029_CR26 ALS Revenfeld (2029_CR5) 2014; 36 C Liu (2029_CR23) 2019; 141 2029_CR24 2029_CR20 R Crescitelli (2029_CR15) 2021; 16 F-C Bidard (2029_CR7) 2014; 15 2029_CR60 P Fuso (2029_CR43) 2021; 11 M Liu (2029_CR44) 2021; 9 NV Chawla (2029_CR40) 2002; 16 2029_CR14 JF Cohen (2029_CR30) 2016; 6 X Yao (2029_CR42) 2020; 24 PMM Ozawa (2029_CR48) 2020; 10 RA Hubbard (2029_CR4) 2011; 155 2029_CR59 2029_CR16 D Ghosh (2029_CR39) 2005; 2005 2029_CR17 2029_CR10 D Eiger (2029_CR25) 2021; 13 P-G Moon (2029_CR54) 2016; 22 2029_CR55 2029_CR12 2029_CR13 Y Koi (2029_CR49) 2020; 111 2029_CR51 H Shen (2029_CR21) 2023; 191 2029_CR52 2029_CR53 JE Medina (2029_CR11) 2023; 11 KK Nicodemus (2029_CR50) 2009; 25 D Risso (2029_CR34) 2014; 32 MW Kim (2029_CR46) 2021; 112 H Shen (2029_CR57) 2024; 24 |
| References_xml | – volume: 6 issue: 11 year: 2016 ident: 2029_CR30 publication-title: BMJ Open. doi: 10.1136/bmjopen-2016-012799 – volume: 191 year: 2023 ident: 2029_CR21 publication-title: Resuscitation. doi: 10.1016/j.resuscitation.2023.109937 – ident: 2029_CR16 doi: 10.1002/wnan.1835 – volume: 22 start-page: 1757 issue: 7 year: 2016 ident: 2029_CR54 publication-title: Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-15-0654 – volume: 141 start-page: 3817 issue: 9 year: 2019 ident: 2029_CR23 publication-title: Journal of the American Chemical Society. doi: 10.1021/jacs.9b00007 – volume: 25 start-page: 1884 issue: 15 year: 2009 ident: 2029_CR50 publication-title: Bioinformatics. doi: 10.1093/bioinformatics/btp331 – ident: 2029_CR55 doi: 10.1038/s41598-019-50084-5 – ident: 2029_CR59 doi: 10.1007/978-1-0716-3323-6_16 – ident: 2029_CR60 doi: 10.1007/s00262-023-03606-0 – volume: 11 issue: 9 year: 2023 ident: 2029_CR11 publication-title: Journal for ImmunoTherapy of Cancer. doi: 10.1136/jitc-2022-006013 – ident: 2029_CR12 doi: 10.1016/j.pharmthera.2021.107806 – ident: 2029_CR47 doi: 10.1186/s13058-016-0753-x – volume: 32 start-page: 896 issue: 9 year: 2014 ident: 2029_CR34 publication-title: Nature Biotechnology. doi: 10.1038/nbt.2931 – ident: 2029_CR8 doi: 10.1093/jncics/pkz026 – volume: 13 start-page: 1015 issue: 5 year: 2021 ident: 2029_CR25 publication-title: Cancers. doi: 10.3390/cancers13051015 – ident: 2029_CR3 – volume: 24 start-page: 3403 issue: 14 year: 2024 ident: 2029_CR57 publication-title: Lab on a Chip. doi: 10.1039/D4LC00331D – ident: 2029_CR41 doi: 10.1038/s41467-023-41132-w – volume: 135 start-page: 55 issue: 1 year: 2011 ident: 2029_CR27 publication-title: Archives of Pathology & Laboratory Medicine. doi: 10.5858/2010-0454-RAR.1 – volume: 126 start-page: 2971 issue: 13 year: 2020 ident: 2029_CR2 publication-title: Cancer. doi: 10.1002/cncr.32859 – ident: 2029_CR32 doi: 10.1002/admt.202201622 – volume: 227 start-page: 658 issue: 2 year: 2012 ident: 2029_CR22 publication-title: Journal of Cellular Physiology. doi: 10.1002/jcp.22773 – volume: 9 year: 2021 ident: 2029_CR44 publication-title: PeerJ. doi: 10.7717/peerj.12147 – volume: 26 start-page: 3248 issue: 13 year: 2020 ident: 2029_CR19 publication-title: Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-19-3313 – volume: 111 start-page: 2104 issue: 6 year: 2020 ident: 2029_CR49 publication-title: Cancer Science. doi: 10.1111/cas.14393 – ident: 2029_CR53 doi: 10.1039/D0LC00096E – ident: 2029_CR24 doi: 10.1186/s13058-020-01323-5 – volume: 9 start-page: 4906 issue: 13 year: 2003 ident: 2029_CR29 publication-title: Clin Cancer Res. – ident: 2029_CR51 doi: 10.1093/database/bay003 – ident: 2029_CR10 doi: 10.1038/s41598-023-42726-6 – ident: 2029_CR26 doi: 10.1002/gcc.23264 – volume: 10 start-page: 150 issue: 1 year: 2020 ident: 2029_CR48 publication-title: Biomolecules. doi: 10.3390/biom10010150 – ident: 2029_CR14 doi: 10.3389/fimmu.2018.00738 – ident: 2029_CR13 doi: 10.3389/fendo.2023.1202493 – volume: 155 start-page: 481 issue: 8 year: 2011 ident: 2029_CR4 publication-title: Annals of Internal Medicine. doi: 10.7326/0003-4819-155-8-201110180-00004 – volume: 36 start-page: 830 issue: 6 year: 2014 ident: 2029_CR5 publication-title: Clinical Therapeutics. doi: 10.1016/j.clinthera.2014.05.008 – ident: 2029_CR9 doi: 10.1186/s12943-021-01330-w – volume: 15 start-page: 406 issue: 4 year: 2014 ident: 2029_CR7 publication-title: The Lancet oncology. doi: 10.1016/S1470-2045(14)70069-5 – volume: 11 start-page: 11182 issue: 11 year: 2017 ident: 2029_CR18 publication-title: ACS nano. doi: 10.1021/acsnano.7b05503 – volume: 122 start-page: 437 issue: 2 year: 2011 ident: 2029_CR28 publication-title: Gynecologic oncology. doi: 10.1016/j.ygyno.2011.04.035 – ident: 2029_CR35 doi: 10.1186/s13059-014-0550-8 – volume: 2005 start-page: 147 issue: 2 year: 2005 ident: 2029_CR39 publication-title: BioMed Research International. doi: 10.1155/JBB.2005.147 – volume: 11 start-page: 816 issue: 8 year: 2021 ident: 2029_CR43 publication-title: Journal of Personalized Medicine. doi: 10.3390/jpm11080816 – volume: 16 start-page: 321 year: 2002 ident: 2029_CR40 publication-title: Journal of Artificial Intelligence Research. doi: 10.1613/jair.953 – volume: 4 start-page: 1900307 issue: 12 year: 2020 ident: 2029_CR58 publication-title: Adv Biosyst doi: 10.1002/adbi.201900307 – ident: 2029_CR6 doi: 10.1186/s12943-023-01741-x – ident: 2029_CR52 doi: 10.1039/C7LC00955K – volume: 24 start-page: 9560 issue: 17 year: 2020 ident: 2029_CR42 publication-title: Journal of Cellular and Molecular Medicine. doi: 10.1111/jcmm.15367 – volume: 186 start-page: 84 issue: 1 year: 1997 ident: 2029_CR33 publication-title: Journal of Microscopy. doi: 10.1046/j.1365-2818.1997.1940755.x – ident: 2029_CR20 doi: 10.1093/braincomms/fcab151 – volume: 12 start-page: 77 issue: 1 year: 2011 ident: 2029_CR36 publication-title: BMC Bioinformatics. doi: 10.1186/1471-2105-12-77 – ident: 2029_CR38 doi: 10.1093/nar/gkad431 – volume: 16 start-page: 1548 issue: 3 year: 2021 ident: 2029_CR15 publication-title: Nature Protocols. doi: 10.1038/s41596-020-00466-1 – volume: 95 start-page: 7665 issue: 19 year: 2023 ident: 2029_CR56 publication-title: Analytical Chemistry. doi: 10.1021/acs.analchem.3c00624 – volume: 21 start-page: 1389 issue: 11 year: 2014 ident: 2029_CR37 publication-title: IEEE Signal Processing Letters. doi: 10.1109/LSP.2014.2337313 – ident: 2029_CR45 doi: 10.3892/mmr.2019.10669 – ident: 2029_CR1 doi: 10.3322/caac.21763 – ident: 2029_CR31 doi: 10.1186/s12859-016-0994-9 – volume: 112 start-page: 5078 issue: 12 year: 2021 ident: 2029_CR46 publication-title: Cancer Science. doi: 10.1111/cas.15155 – ident: 2029_CR17 doi: 10.1038/s41598-023-39746-7 |
| SSID | ssj0017858 |
| Score | 2.4662507 |
| Snippet | Background
Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However,... Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography... Background Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However,... BackgroundMammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However,... Abstract Background Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer.... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 90 |
| SubjectTerms | Adult Aged BI-RADS 4 breast lesions Biological markers Biomarkers Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Biomedical and Life Sciences Biomedicine Biopsy Breast cancer Breast Neoplasms - blood Breast Neoplasms - diagnosis Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer Cancer Research Carcinoma CD24 Antigen - genetics CD24 Antigen - metabolism Classification Diagnosis Early detection biomarkers Early Detection of Cancer - methods ErbB-2 protein Ethylenediaminetetraacetic acid Extracellular vesicles Extracellular Vesicles - genetics Extracellular Vesicles - metabolism Female Humans Hyperplasia Immunohistochemistry Invasiveness Lesions Liquid Biopsy Malignancy Mammography Metastases MicroRNA MicroRNAs MicroRNAs - blood MicroRNAs - genetics Middle Aged miRNA MiRNA sequencing Neoplasm Staging Next-generation sequencing Oncology Pathology Patients Plasma Prospective Studies Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Subpopulations Surgical Oncology |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgSIgXBBuXjIGMhOChWEscJ3GeUBmbKqTtYWJS3yzfsk2iaUnaIf495zhJR4bgLapdxc65-Ds-N0LeJSWwkRaC-YILJkRVMeOlYVkptcuMr2woVn16ls8uxNd5Nu8v3No-rHLQiUFRu6XFO_LDlGOdmBSO80-rHwy7RqF3tW-hcZ88SACJYOuGYr41uLDxvOyyizKWiSQZkmZkftiC7s4kw2auAJh4yfjoYAr1-__W0n8cU3dDKO_4UcPxdPKEPO5xJZ12jPCU3PP1Ltmb1mBTL37R9zREeoYr9F3y8LR3qO-Rn4vr87MpBZXgv1NMNaGz43M-obp29OgLFxO6Ani90BR0eKPxlh_DVumNb_E1tN2Y1bYDWEt1SzGdHyN-mpYuK-qxfDIDAHrpqcHw9zW1yGbNM3JxcvztaMb6XgzMAsJas9RWnvMqN4nOQS3keeVibVOnixQwg_W6cGCZADbLU-d0ZTG7waWF4QA5NJc-fU526mXtXxKqBZgoRiZFJbRIiriUsYk1EKuyZcxNEpHJQAi16kpuqGCqyFx1ZFNANhXIpnhEPiOttjOxXHb4Ydlcql76lDMSkKPViQfEJLnQpoQn7hJpSmBhEZEPSGmFQo1fU_e5CbBgLI-lplKgLzwrYXEHo5kgjHY8PPCK6pVBq25ZNyJvt8P4Twxwq_1yg3PivATjlZcRedGx1nZLAhQtuscjIkdMN9rzeKS-vgqlwjEzOi-KNCIfB_68Xde_P-r-_7fxijziQXIyxvkB2Vk3G_8asNnavAkC-BtSjzNI priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Nb9MwFLfQkBAXBBsfgYGMhOBQLBLHcZxjKZsqpO0wMWk3y58waU2rpt3Ef897blqWAQduVeyoTt6Hfy_vvZ8JeVc0oEZGCBZqLpgQMTIblGVVo4yvbIgukVWfnMrpufh6UV30NDnYC3M7f18o-akDH1sphoeuArDhDQN3e7-Ci6jNEznZZQxqValtU8xf7xtsPImf_08vfGsbulsieSdPmraf48fkUY8b6Xgj6CfkXmj3ycG4hZh59pO-p6mSM30i3ycPTvqE-QG5mV2enY4pmHy4othKQqdHZ3xETevp5AsXI7oA-DwzFHz00uBXfCxLpdehw7-h3doudid8ddR0FNv1saJn2dF5pAHpkRkAzO-BWixvX1GHarR8Ss6Pj75Npqw_a4E5QFArVroYOI_SFkaC2UsZfW5c6U1dAiZwwdQeIg_AXrL03kSH3Qu-rC0HSGG4CuUzstfO2_CCUCMgBLGqqKMwoqjzRuU2NyCg6Jqc2yIjo60g9GJDqaFTKKKk3ohNg9h0EpvmGfmMstrNRDrsdAG0RPfWpb1VgAydKQIgIsWFsQ384r5QtgEVFRn5gJLWaLT4Nk3fewALRvorPVYCc91VA4s7HMwEY3PD4a2u6N7YO11ypDAqAWlm5O1uGO_EArY2zNc4J5cNBKe8ycjzjWrtHkmAI8X0d0bUQOkGzzwcaS9_JCpw7HyWdV1m5ONWP3-v698v9eX_TX9FHvJkSRXj_JDsrZbr8Bqw2Mq-SUb4C0rqKkY priority: 102 providerName: Springer Nature |
| Title | miRNA panel from HER2+ and CD24+ plasma extracellular vesicle subpopulations as biomarkers of early-stage breast cancer |
| URI | https://link.springer.com/article/10.1186/s13058-025-02029-2 https://www.ncbi.nlm.nih.gov/pubmed/40405296 https://www.proquest.com/docview/3216563392 https://www.proquest.com/docview/3206987129 https://pubmed.ncbi.nlm.nih.gov/PMC12096773 https://doaj.org/article/db8232ca1e074824ab9e072d18b9cca4 |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9MwFLdgSIgLgo2PjFEZCcGhWEscJ3aObelUIa1CFZUqLpadOGMSTaumHeK_5z0nLcsQ4sIlamtXcfy-8977mZC3UQZsZIRgTnLBhChLZp2yLMmUKRLrytyDVV9O08lcfFoki1tHfWFNWAMP3GzceWEVGP3cRA6MneLC2Aw-8SJSNoO7eyTQMAv3wVSbP5AqUfsWGZWe16CpE8Xw6FZwj3jGeMcMebT-P3XyLaN0t2DyTtbUG6OLJ-Rx60XSQbP6p-Seq47JyaCCCHr5k76jvq7TvzA_Jg8v2_T5CfmxvJ5NBxQUgPtOsbGETsYz3qemKujoIxd9ugZnemkoaOyNwXf6WKRKb1yNt6H1zq4P533V1NQUm_exvmdT01VJHYIlM3A3rxy1WOy-pTky1eYZmV-Mv4wmrD15geXgT21ZnJeO8zK1kUlBCaRpWYQmjwsjY_AQcmdkAXEIeGJpXBSmzLGXoYil5eBgGK5c_JwcVavKvSTUCAhIrIpkKYyIZJip0IYGCFTmWchtFJD-nhB63QBsaB-YqFQ3ZNNANu3JpnlAhkirw0wEx_Y_AMvolmX0v1gmIO-R0hpFGHfTtJ0IsGAEw9IDJTDznWSwuLPOTBC9vDu85xXdin6tY46ARjH4nQF5cxjGf2I5W-VWO5wTphmEqjwLyIuGtQ6PJECtYjI8IKrDdJ1n7o5U1988MDj2QadSxgH5sOfP3-v6-6ae_o9NfUUecS9fCeP8jBxtNzv3Gvy1re2R-3Ihe-TBcDz9PINvo3TU8-IK19nwK1znfPALL00_rw |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEvCDY-AgOMxMdDsZY4TuI8TKjbOnVsrVC1SXszduKMSTQtTcu0f46_jTs36egQvO2tqp3Wzp3vfuf7IuRtkAIbaSGYTbhgQhQFM1YaFqVS55GxReaKVfcHce9UfD6LztbIryYXBsMqG5noBHU-zvCOfDvkWCcmBHX-afKDYdco9K42LTR03Voh33ElxurEjiN7dQkmXLVzuA_0fsf5Qfdkr8fqLgMsA-wwY2FWWM6L2AQ6BoaP4yL3dRbmOglBG2ZWJzlgbkAdcZjnusgwbj8PE8NBmWoubQi_e4esC7xAaZH13e7gy3Dpx0ik6xAK4ihikQiCJm1HxtsVaI9IMmwnC5CNp4yvqEbXQeBvPfGHorwZxHnDk-sU5MFD8qBGtrSzYMVHZM2WG2SzU4JVP7qi76mLNXWX-Bvkbr926W-Sy9HFcNChIJTsd4rJLrTXHfI21WVO9_a5aNMJAPyRpqBFphr9DBg4S3_aCv-GVnMzWfYgq6iuKBYUwJijaUXHBbVYwJkBBD631GAA_oxmyOjTx-T0Vuj0hLTKcWmfEaoFGElGBkkhtAgSP5W-8TUQq8hSn5vAI-2GEGqyKPqhnLEkY7UgmwKyKUc2xT2yi7RazsSC3e6L8fRc1edf5UYCds10YAGzSS60SeETzwNpUjhEwiMfkNIKxQq-TV1nR8CCsUCX6kiB3vgohcVtrcwEcZCtDje8ompxVKnrw-ORN8thfBJD7Eo7nuMcP07BfOapR54uWGu5JQGiHh30HpErTLey59WR8uKbK1aOudlxkoQe-djw5_W6_v1Sn_9_G6_Jvd5J_1gdHw6OXpD73J2iiHG-RVqz6dy-BKQ4M6_q40jJ19uWAL8BjZR2ug |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfQkCZeEGx8hA0wEoKHEi1xHMd5LN2q8rEKTUzam2XH9phE06pph_jvuXPSsgx44K2KHdXJffh3ubufCXmdlqBGmvPYFYzHnHsfGydNnJdS29w4XwWy6tOpmJzzjxf5xY0u_lDtvklJtj0NyNJUr44W1rcmLsVRA543lzEexQpwh5UxOOG7yNWFRX0jMdrmEQqZy02rzF_v621HgbX_T998Y3O6XTh5K3saNqXxA3K_Q5N02Ir_Ibnj6j2yP6whkp79pG9oqO8MH873yO5pl0bfJz9mV2fTIQVH4L5TbDChk5MzNqC6tnR0zPiALgBUzzQFz73U-G0fi1XptWvwb2izNovtuV8N1Q3FJn6s81k2dO6pQ9LkGGDnpaMGi95XtELlWj4i5-OTr6NJ3J3AEFeAq1ZxVnnHmBcm1QKcgRDeJrrKrC4yQAqV04WFeAQQmcis1b7CngabFYYB0NBMuuwx2anntXtKqOYQmBiZFp5rnhZJKROTaBCQr8qEmTQig40g1KIl2lAhQJFCtWJTIDYVxKZYRN6jrLYzkSQ7XJgvL1Vnc8oaCXix0qkDnCQZ16aEX8ym0pSguDwib1HSCk0Z36buOhJgwUiKpYaSYwY8L2Fxh72ZYIJVf3ijK6pzAY3KGBIbZYA_I_JqO4x3Yllb7eZrnJOIEkJWVkbkSata20fi4F4xKR4R2VO63jP3R-qrb4EgHPuhRVFkEXm30c_f6_r3S332f9Nfkt0vx2P1-cP00wG5x4JR5TFjh2RntVy75wDWVuZFsMdfjUM1hQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=miRNA+panel+from+HER2%2B+and+CD24%2B+plasma+extracellular+vesicle+subpopulations+as+biomarkers+of+early-stage+breast+cancer&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Spychalski%2C+Griffin+B.&rft.au=Lin%2C+Andrew+A.&rft.au=Yang%2C+Stephanie+J.&rft.au=Shen%2C+Hanfei&rft.date=2025-05-22&rft.issn=1465-542X&rft.eissn=1465-542X&rft.volume=27&rft.issue=1&rft_id=info:doi/10.1186%2Fs13058-025-02029-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13058_025_02029_2 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon |